Skip to content

Non-Comparative Study of Open Abdomen That Require the Use of Negative Pressure Wound Therapy (NPWT) for Temporary Abdominal Closure

A Prospective, Non-Comparative, Open, Multi-Center Study to Assess the Use of a New Negative Pressure Wound Therapy (NPWT) System (RENASYS Touch and RENASYS AB) in Temporary Abdominal Closure (TAC) For the Management of the Open Abdomen

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03431220
Enrollment
0
Registered
2018-02-13
Start date
2016-12-31
Completion date
2017-12-31
Last updated
2018-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdomenal Wound Trauma

Brief summary

A study in which subjects with a Grade 1 or Grade 2 open abdomen that require the use of NPWT for temporary abdominal closure. Subjects will use the NPWT system for up to 14 days, with a 21 day post study initiation follow-up assessment for latent complications and mortality.

Interventions

DEVICERENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device

NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.

Sponsors

Smith & Nephew, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Eligible subjects must be properly consented before enrollment. If the subject is incapable of providing consent, emergency consent procedures will be followed, or the subject's legal representative must be asked to provide consent on the subject's behalf, per the IRB guidelines. 2. Subjects must be at least eighteen (18) yeaTS of age, or older. 3. Males and non-pregnant females. 4. Grade 1 or Grade 2 open abdomen patients who would benefit from temporary abdominal closure (TAC) with topical Negative Pressure Wound Therapy (NPWT).

Exclusion criteria

1. Grade 3 and Grade 4 open abdomens. 2. Malignancy in the reference wound bed or margins of the wound. 3. Patients with non-enteric unexplored fistulas. 4. High risk for imminent death, as determined by the attending surgeon and Principal Investigator (PI). 5. Pre-existing large ventral hernia. 6. Significant loss of abdominal wall fascia as a result of trauma or infection. 7. Patients with a known hist01y of poor compliance with medical treatment. 8. Patients who have participated in this trial previously and who were withdrawn.

Design outcomes

Primary

MeasureTime frameDescription
To determine the number of days taken to achieve delayed primary fascial closure.14 daysNPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.

Secondary

MeasureTime frame
To confirm the performance of the NPWT system in terms of: management of peritoneal fluid14 days
To confirm the performance of the NPWT system in terms of reduction in edema14 days
To confirm the performance of the NPWT system in terms of prevention of fixity14 days
To confirm the performance of the NPWT system in terms of prevention of infection14 days
To assess the ability of the NPWT system to prevent further deterioration of the open abdomen as classified by Bjorck et al., (2009)14 days
To confirm the performance of the NPWT system in terms of maintenance of abdominal tissue domain14 days
To assess the number of days to achieve final closure of the open abdomen14 days
To monitor the length of stay (days) in ICU and length of stay in hospital14 days
To monitor the number and type of re-operations throughout the course of the study14 days
To assess the number of dressing changes14 days
To record clinicians' overall opinion on the usability of the new device throughout the study14 days
To determine the type (method) of final closure of the open abdomen14 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026